TY - JOUR
T1 - Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma
T2 - Systematic review and meta-analysis
AU - Mohyuddin, Ghulam Rehman
AU - Aziz, Muhammad
AU - McClune, Brian
AU - Abdallah, Al Ola
AU - Qazilbash, Muzaffar
N1 - Publisher Copyright:
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Objective: Ascertain the benefit of prophylactic antibiotics for patients with newly diagnosed multiple myeloma (MM), given that clinical trials evaluating this have had conflicting results. Methods: We performed a systematic review and meta-analysis evaluating the use of prophylactic antibiotics in patients with MM and its impact on infection risk and mortality. Results: Across three included studies, a total of 664 patients received antibiotics and 650 patients received no antibiotics. The overall incidence of infection within 3 months was lower for antibiotic group compared to placebo (18.4% vs 23.4%, RR: 0.79, 95% CI 0.62-1.00, P =.05, I2 = 6.5%). There was no difference in mortality in the first 3 months (1.5% vs 3.5%, RR: 0.47, 95% CI 0.17-1.27, P =.60, I2 = 28.1%). Conclusion: Antibiotic prophylaxis for a finite duration can decrease the overall incidence of infection within the first 3 months following diagnosis. This does not lead to a decrease in mortality. Further data on antibiotic resistance patterns, toxicity, healthcare expenditures, and the impact of antibiotics on subsequent therapies can assist providers in helping make decisions on prophylactic antibiotics with their patients.
AB - Objective: Ascertain the benefit of prophylactic antibiotics for patients with newly diagnosed multiple myeloma (MM), given that clinical trials evaluating this have had conflicting results. Methods: We performed a systematic review and meta-analysis evaluating the use of prophylactic antibiotics in patients with MM and its impact on infection risk and mortality. Results: Across three included studies, a total of 664 patients received antibiotics and 650 patients received no antibiotics. The overall incidence of infection within 3 months was lower for antibiotic group compared to placebo (18.4% vs 23.4%, RR: 0.79, 95% CI 0.62-1.00, P =.05, I2 = 6.5%). There was no difference in mortality in the first 3 months (1.5% vs 3.5%, RR: 0.47, 95% CI 0.17-1.27, P =.60, I2 = 28.1%). Conclusion: Antibiotic prophylaxis for a finite duration can decrease the overall incidence of infection within the first 3 months following diagnosis. This does not lead to a decrease in mortality. Further data on antibiotic resistance patterns, toxicity, healthcare expenditures, and the impact of antibiotics on subsequent therapies can assist providers in helping make decisions on prophylactic antibiotics with their patients.
KW - antibiotic
KW - myeloma
KW - prophylaxis
UR - http://www.scopus.com/inward/record.url?scp=85083911684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083911684&partnerID=8YFLogxK
U2 - 10.1111/ejh.13374
DO - 10.1111/ejh.13374
M3 - Article
C2 - 31880853
AN - SCOPUS:85083911684
SN - 0902-4441
VL - 104
SP - 420
EP - 426
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 5
ER -